Keck School Faculty

Louis VanderMolen, MD
Louis VanderMolen, MD
Professor of Clinical Medicine
NOR 1441 Eastlake Ave Health Sciences Campus Los Angeles
Dr. VanderMolen earned his medical degree from Loyola University Stritch School of Medicine. He performed his Internal Medicine Internship and Residency from Baylor College of Medicine- Texas Medical Center. He then went on to complete two fellowships, the first in hematology at Baylor, and the second in oncology at National Cancer Institute- Clinical Oncology Program.

Orange County Medical Association: Physician of Excellence Award, 2006-2013

Orange County Medical Association: Ooops. Something went wrong., 2006-2013

Baylor College of Medicine: Chief Resident, Internal Medicine, 1983-1984

Baylor College of Medicine: Ooops. Something went wrong., 1983-1984

Phi Beta Kappa: Elected Member, 1977

Phi Beta Kappa: Ooops. Something went wrong., 1977

Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm. 2012 Aug; 27(6):337-43.. View in PubMed

A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer Am J Otolaryngol. 2012 Jan-Feb; 33(1):93-7. . View in PubMed

Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm. 2011 Jun; 26(3):273-7.. View in PubMed

High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants Am J Clin Oncol. 2005 Jun; 28(3):281-8. . View in PubMed

Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma Cancer Biother Radiopharm. 2004 Oct; 19(5):570-80. . View in PubMed

Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol. 2003 Apr; 26(2):141-5.. View in PubMed

Successful treatment of transitional cell carcinoma of the urethra with chemotherapy Cancer Invest. 2002; 20(2):206-7. . View in PubMed

Powered by SC CTSI
Go to Top